A previous study related EGFR L861Q to the resistance of EGFR-TKI therapy in lung cancer7, which suggests that this improved cancer specificity in advanced tumors might be attributed to the result of selection during targeted cancer therapies. The gene discussed is EGFR; the disease is cancer.